₹33.3
▼ -0.38 -1.13%
18 Jul 2026
NSE Listed
Biofil Chem & Pharma Ltd. (BIOFILCHEM)
Volume: 9,944Avg Vol 1W: 6,866.8Avg Vol 1M: 8,450.0552W Range:₹25.6₹47.55
Key Ratios
Checked 19h agoMarket Cap₹54 Cr
Current Price₹33.3
Previous Close₹33.68
High / Low (52w)₹47.55 / ₹25.6
Volume9,944
Avg Vol (1W)6,866.8
Avg Vol (1M)8,450.05
Stock P/E120.97
Book Value₹11.54
Dividend Yield—
ROE1.1%
ROA—
Revenue (TTM)₹34 Cr
Revenue Growth—
Profit Margin—
Total Debt₹0 Cr
Shares Outstanding—
Face Value₹10
EPS (TTM)₹0.34
P/B3.56
Debt / Equity0.02
50 DMA₹34.53
200 DMA₹34.6
Day change-1.13%
Price Chart
₹33.3▼ 27.78% · 1Y
2025-07-172026-07-16
20-day avg volume: 8K shares
Pros
- Company is almost debt-free.
Cons
- Revenue fell 18% YoY.
- Stock trades at a high P/E of 121.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹2 Cr | ₹14 Cr | ₹8 Cr | ₹6 Cr | ₹14 Cr | ₹1 Cr | ₹8 Cr |
| EBITDA | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net Profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹12 Cr | ₹23 Cr | ₹30 Cr | ₹37 Cr | ₹23 Cr | ₹30 Cr | ₹41 Cr | ₹34 Cr |
| EBITDA | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Net Profit | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| EPS | 0.29 | 0.3 | 0.74 | 0.77 | 0.44 | 0.34 | 0.44 | 0.34 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹24 Cr | ₹24 Cr | ₹42 Cr | ₹33 Cr | ₹19 Cr | ₹31 Cr | ₹47 Cr | ₹51 Cr |
| Total Liabilities | ₹11 Cr | ₹11 Cr | ₹27 Cr | ₹17 Cr | ₹2 Cr | ₹14 Cr | ₹29 Cr | ₹32 Cr |
| Equity | ₹13 Cr | ₹14 Cr | ₹15 Cr | ₹16 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr | ₹19 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹-2 Cr |
| Investing | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Financing | ₹-1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Free Cash Flow | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹-2 Cr |
Shareholding
Promoter 46.79% Institutions 0.08% Public 53.13%
Efficiency & Working Capital
ROCE1.6%
Interest Coverage19.5
Dividend Payout—
Debtor Days419 d
Inventory Days37 d
Payable Days339 d
Cash Conversion Cycle117 d
Working Capital Days455 d
Shareholding Details
As of 2026-03-31
Promoter46.8%
FII0%
DII0.1%
Institutions0.1%
Public53.1%
Promoter Pledge0%
No. of Shareholders25,356
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% | 46.8% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Public | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% | 53.1% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 26,741 | 26,123 | 25,864 | 26,581 | 25,480 | 26,422 | 26,114 | 25,914 | 25,685 | 25,196 | 24,825 | 25,356 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Scope Finance Company Private Limited | Shareholding of Promoter and Promoter Group | 13.9% | 22,62,500 |
| Starline Equifin Private Limited | Public Shareholding | 7.5% | 12,21,368 |
| Mid (india) Pharmaceuticals Pvt Ltd | Shareholding of Promoter and Promoter Group | 7.2% | 11,75,250 |
| Cyano Finance And Sales Pvt. Ltd. | Shareholding of Promoter and Promoter Group | 5.4% | 8,76,450 |
| Meena Shah | Shareholding of Promoter and Promoter Group | 4.1% | 6,60,312 |
| Niyati Shah | Shareholding of Promoter and Promoter Group | 4.1% | 6,59,312 |
| Ketan Shah | Shareholding of Promoter and Promoter Group | 3% | 4,93,062 |
| Sandeep Shah | Shareholding of Promoter and Promoter Group | 2.6% | 4,23,812 |
| Romil Shah | Shareholding of Promoter and Promoter Group | 2.4% | 3,82,550 |
| Ksl And Industries Limited | Public Shareholding | 1.9% | 3,08,065 |
| Kishor Himmatsinh Jhala | Public Shareholding | 1.2% | 1,97,836 |
| Smitesh Sanalal Shah | Shareholding of Promoter and Promoter Group | 1.2% | 1,86,662 |
| Gom Industries Ltd | Public Shareholding | 1.1% | 1,80,800 |
| Trupti Shah | Shareholding of Promoter and Promoter Group | 0.6% | 1,01,750 |
| Ritu Shah | Shareholding of Promoter and Promoter Group | 0.6% | 90,100 |
| Manali Simon | Shareholding of Promoter and Promoter Group | 0.5% | 87,200 |
| Meet Shah | Shareholding of Promoter and Promoter Group | 0.5% | 87,200 |
| Rohan Shah | Shareholding of Promoter and Promoter Group | 0.4% | 65,500 |
| Kiran Shah | Shareholding of Promoter and Promoter Group | 0.4% | 63,100 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Meena Shah | 0 | 0% | 2026-03-31 |
| Niyati Shah | 0 | 0% | 2026-03-31 |
| Ketan Shah | 0 | 0% | 2026-03-31 |
| Sandeep Shah | 0 | 0% | 2026-03-31 |
| Romil Shah | 0 | 0% | 2026-03-31 |
| Smitesh Sanalal Shah | 0 | 0% | 2026-03-31 |
| Trupti Shah | 0 | 0% | 2026-03-31 |
| Ritu Shah | 0 | 0% | 2026-03-31 |
| Manali Simon | 0 | 0% | 2026-03-31 |
| Meet Shah | 0 | 0% | 2026-03-31 |
| Rohan Shah | 0 | 0% | 2026-03-31 |
| Kiran Shah | 0 | 0% | 2026-03-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Ketan Shah | Chairman / Executive Director / M D / Promoter | 2025 |
| Meet Shah | Non-Exec & Non-Independent Dir | 2025 |
| Ashok Kumar Ramawat | Independent Non Exe. Director | 2025 |
| Satish Beohar | Independent Non Exe. Director | 2025 |
| Gayatri Padiyar | Independent Non Exe. Director | 2025 |
| Smitesh Shah | Non-Exec & Non-Independent Dir | 2025 |
| Apoorv Jain | Company Sec. & Compli. Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharma | ₹27 Cr | 79.8% |
| Chemicals | ₹7 Cr | 20.2% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 20 | 16 | 16 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 0 | 4 | 4 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 1 | 2 |
Insider / Designated-Person Trades
12 recent disclosure(s)
NIYATI SHAHDisposal · 32,657
MEENA SHAHAcquisition · 32,657
Niyati ShahAcquisition · 4,93,940
MANALI SIMONAcquisition · 87,200
SANDEEP SHAHDisposal · 87,200
KETAN SHAHAcquisition · 42,440
Substantial Acquisitions (SAST)
3 disclosure(s)
Off Market Gift11/03/2024 · 87,200
Off Market Gift11/03/2024 · 87,200
Off Market Gift11/03/2024 · 87,200
Company Information
Incorporated1985
ChairmanKetan Shah
AuditorMaheshwari & Gupta
Investor Email[email protected]; [email protected]
📍 11/12 Sector E Sanwer Road, Sanwer Road Industrial Area, Indore, Madhya Pradesh, 452015
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search